caladrius biosciences, inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. its product candidates include developmental treatments for cardiovascular diseases, such as clbs12 for the treatment of critical limb ischemia; clbs16, which is in phase ii clinical trial for the treatment of coronary microvascular dysfunction; clbs14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. the company was formerly known as neostem, inc. and changed its name to caladrius biosciences, inc. in june 2015. caladrius biosciences, inc. was founded in 1980 and is headquartered in basking ridge, new jersey.
Company profile
Ticker
LSTA
Exchange
Website
CEO
David Mazzo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Caladrius Biosciences, Inc., CALADRIUS BIOSCIENCES, INC., CORNICHE GROUP INC /DE, NeoStem, Inc., PHASE III MEDICAL INC/DE
SEC CIK
Corporate docs
Subsidiaries
Amorcyte, LLC • Athelos Corporation • Cend Therapeutics, Inc. • NeoStem Oncology, LLC • Lisata Therapeutics Australia Pty Ltd • Lisata Therapeutics Ireland Limited • Lisata Therapeutics (U.K.) Limited • As of December 31, 2022, Becton Dickinson's ownership interest in Athelos Corporation ...
IRS number
222343568
LSTA stock data
Latest filings (excl ownership)
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
14 Aug 23
S-8
Registration of securities for employees
13 Jul 23
8-K
Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
11 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
9 May 23
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
8-K
Departure of Directors or Certain Officers
1 May 23
Transcripts
LSTA
Earnings call transcript
2023 Q1
9 May 23
LSTA
Earnings call transcript
2022 Q3
13 Nov 22
LSTA
Earnings call transcript
2022 Q2
5 Aug 22
LSTA
Earnings call transcript
2022 Q1
6 May 22
LSTA
Earnings call transcript
2021 Q4
23 Mar 22
LSTA
Earnings call transcript
2021 Q3
4 Nov 21
LSTA
Earnings call transcript
2021 Q2
6 Aug 21
LSTA
Earnings call transcript
2021 Q1
7 May 21
LSTA
Earnings call transcript
2020 Q4
26 Feb 21
LSTA
Earnings call transcript
2020 Q3
5 Nov 20
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 23.69 mm | 23.69 mm | 23.69 mm | 23.69 mm | 23.69 mm | 23.69 mm |
| Cash burn (monthly) | 1.49 mm | 804.83 k | 2.29 mm | 4.83 mm | 1.39 mm | 1.90 mm |
| Cash used (since last report) | 4.66 mm | 2.52 mm | 7.17 mm | 15.11 mm | 4.36 mm | 5.96 mm |
| Cash remaining | 19.03 mm | 21.17 mm | 16.52 mm | 8.58 mm | 19.33 mm | 17.73 mm |
| Runway (months of cash) | 12.8 | 26.3 | 7.2 | 1.8 | 13.9 | 9.3 |
Institutional ownership, Q2 2023
39.4% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 23 |
| Opened positions | 2 |
| Closed positions | 2 |
| Increased positions | 4 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 2.17 bn |
| Total shares | 3.21 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| CVI Investments | 1.58 mm | $0.00 |
| Intracoastal Capital | 949.61 k | $2.21 mm |
| BML Capital Management | 243.84 k | $902.20 mm |
| Vanguard | 176.14 k | $651.71 mm |
| Renaissance Technologies | 93.32 k | $345.00 k |
| BLK Blackrock | 56.81 k | $210.18 mm |
| Geode Capital Management | 25.97 k | $96.10 mm |
| Citadel Advisors | 17.18 k | $63.56 mm |
| Dimensional Fund Advisors | 14.95 k | $55.32 mm |
| STT State Street | 14.35 k | $53.09 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Sep 23 | Kristen K Buck | Common Stock | Payment of exercise | Dispose F | No | No | 2.18 | 2,908 | 6.34 k | 32,915 |
| 13 Jan 23 | David J Mazzo | Common Stock | Payment of exercise | Dispose F | No | No | 3.65 | 397 | 1.45 k | 96,543 |
| 11 Jan 23 | David J Mazzo | Common Stock | Payment of exercise | Dispose F | No | No | 3.2 | 1,030 | 3.30 k | 96,940 |
| 10 Jan 23 | Kristen K Buck | Common Stock | Payment of exercise | Dispose F | No | No | 3.195 | 512 | 1.64 k | 35,823 |
| 10 Jan 23 | David J Mazzo | Common Stock | Payment of exercise | Dispose F | No | No | 3.195 | 3,470 | 11.09 k | 97,970 |
| 9 Jan 23 | Kristen K Buck | Common Stock | Payment of exercise | Dispose F | No | No | 3 | 2,147 | 6.44 k | 36,335 |
| 9 Jan 23 | Kristen K Buck | Common Stock | Grant | Acquire A | No | No | 0 | 18,000 | 0.00 | 38,482 |
| 9 Jan 23 | Kristen K Buck | Stock Options Common Stock | Grant | Acquire A | No | No | 3 | 9,000 | 27.00 k | 9,000 |
| 9 Jan 23 | David J Mazzo | Common Stock | Payment of exercise | Dispose F | No | No | 3 | 7,845 | 23.54 k | 101,440 |
| 9 Jan 23 | David J Mazzo | Common Stock | Grant | Acquire A | No | No | 0 | 60,000 | 0.00 | 109,285 |
Press releases
Lisata Therapeutics Announces Participation in Upcoming Conferences in September
5 Sep 23
Impilo Therapeutics Launches to Enable Nucleic Acid-Based Medicines to Effectively Treat Solid Tumor Cancers
15 Aug 23
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma
8 Aug 23
Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time
7 Aug 23